

# Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/TDEF22552157EN.html>

Date: June 2020

Pages: 158

Price: US\$ 3,500.00 (Single User License)

ID: TDEF22552157EN

## Abstracts

Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020

### SUMMARY

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 46 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 – Pipeline Review, H1 2020, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 8, 3, 14 and 8 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Metabolic Disorders, Cardiovascular, Ophthalmology, Gastrointestinal, Immunology, Genetic Disorders, Oncology and Respiratory which include indications Neuropathic Pain (Neuralgia), Pain, Osteoarthritis Pain, Cancer Pain, Diabetic Peripheral Neuropathy, Ocular Pain (Eye Pain), Postherpetic Neuralgia, Pruritus, Inflammatory Pain, Keratoconjunctivitis Sicca (Dry Eye), Visceral Pain, Alzheimer's Disease, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Blepharospasm, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Chronic Heart Failure, Cluster Headache Syndrome (Cluster Headache), Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Hypertension, Infantile Spasm (West Syndrome), Inflammation, Insomnia, Irritable Bowel Syndrome, Ischemia Reperfusion Injury, Myocardial Infarction, Non-Alcoholic Steatohepatitis (NASH), Ocular Hypertension, Ocular Inflammation, Open-Angle Glaucoma, Parkinson's Disease, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Schizophrenia, Skin Inflammation, Squamous Cell Carcinoma, Tremor, Tuberos Sclerosis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

The report reviews Transient Receptor Potential Cation Channel Subfamily V

Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1)  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by AlzeCure Pharma AB, H1 2020  
Pipeline by Amorepacific Corp, H1 2020  
Pipeline by AntalGenics SL, H1 2020  
Pipeline by Astellas Pharma Inc, H1 2020  
Pipeline by Bsense Bio Therapeutics Ltd, H1 2020  
Pipeline by Centrexion Therapeutics Corp, H1 2020  
Pipeline by Cmxtwenty, H1 2020  
Pipeline by Concentric Analgesics Inc, H1 2020  
Pipeline by GB Sciences Inc, H1 2020  
Pipeline by GBSciences Inc, H1 2020  
Pipeline by Grunenthal GmbH, H1 2020  
Pipeline by GW Pharmaceuticals Plc, H1 2020  
Pipeline by Interventional Analgesix Inc, H1 2020  
Pipeline by Ion Channel Pharmacology LLC, H1 2020  
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020  
Pipeline by Medifron DBT Co Ltd, H1 2020  
Pipeline by Mestex AG, H1 2020  
Pipeline by Neurim Pharmaceuticals Ltd, H1 2020  
Pipeline by Novartis AG, H1 2020

Pipeline by Oblique Therapeutics AB, H1 2020  
Pipeline by Pila Pharma AB, H1 2020  
Pipeline by Revive Therapeutics Ltd, H1 2020  
Pipeline by Scopus BioPharma Inc, H1 2020  
Pipeline by Serentrix LLC, H1 2020  
Pipeline by Sorrento Therapeutics Inc, H1 2020  
Pipeline by Sylentis SAU, H1 2020  
Pipeline by Vitality Biopharma Inc, H1 2020  
Pipeline by Winston Pharmaceuticals Inc, H1 2020  
Pipeline by Young BioPharma LLC, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Dormant Products, H1 2020 (Contd..3), H1 2020  
Dormant Products, H1 2020 (Contd..4), H1 2020  
Dormant Products, H1 2020 (Contd..5), H1 2020  
Dormant Products, H1 2020 (Contd..6), H1 2020  
Discontinued Products, H1 2020  
Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

AlzeCure Pharma AB  
Amorepacific Corp  
AntalGenics SL  
Astellas Pharma Inc  
Bsense Bio Therapeutics Ltd  
Centrexion Therapeutics Corp  
Cmxtwenty  
Concentric Analgesics Inc  
GB Sciences Inc  
GBSciences Inc  
Grunenthal GmbH  
GW Pharmaceuticals Plc  
Interventional Analgesix Inc  
Ion Channel Pharmacology LLC  
Jeil Pharmaceutical Co Ltd  
Medifron DBT Co Ltd  
Mestex AG  
Neurim Pharmaceuticals Ltd  
Novartis AG  
Oblique Therapeutics AB  
Pila Pharma AB  
Revive Therapeutics Ltd  
Scopus BioPharma Inc



Serentrix LLC  
Sorrento Therapeutics Inc  
Sylentis SAU  
Vitality Biopharma Inc  
Winston Pharmaceuticals Inc  
Young BioPharma LLC

## I would like to order

Product name: Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/TDEF22552157EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TDEF22552157EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

